Jasper Therapeutics to Merge With Kira Pharmaceuticals in Strategic Deal
JSPR has more than doubled off its 52-week low of $0.315.
Summary
Jasper Therapeutics announced a merger with Kira Pharmaceuticals, following its June 1 strategic review and going-concern warning. The deal provides a lifeline for the cash-strapped biotech, which had just $14.1 million in reserves as of Q1 and faced Nasdaq delisting. The combined company will focus on advancing a consolidated pipeline of potential best-in-class innovative therapies for immunologically-driven disorders. Jasper completed the acquisition of Kira and secured $132 million in financing through a private placement, with proceeds expected to fund development of the combined company's pipeline through the second half of 2028. The transaction represents a concrete outcome of the strategic alternatives process, potentially preserving shareholder value through combination rather than liquidation. Integration risks and Kira's pipeline will be key to long-term viability.
At the time of this announcement, JSPR was trading at $0.74 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $21.7M. The 52-week trading range was $0.32 to $3.52. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: Dow Jones Newswires.